• PDF-version
• Print
• Email this

[1] Schultz-Zehden B. Körpererleben im Klimakterium. Journal für Menopause 1998; 5: 10-17.

[2] Walter CA. The psychosocial meaning of menopause: women's experiences. J Women Aging 2000; 12: 117-131.

[3] Avis NE, McKinlay SM. The Massachusetts Women's Health Study: an epidemiologic investigation of the menopause. J Am Med Womens Assoc 1995; 50: 45-49.

[4] Hvas L. Positive aspects of menopause: a qualitative study. Maturitas 2001; 39: 11-17.

[5] Utian WH, Boggs PP. The North American Menopause Society 1998 Menopause Survey. Part I: postmenopausal women's perceptions about menopause and midlife. Menopause 1999; 6: 122-128.

[6] Papini DR, Intrieri RC, Goodwin PE. Attitude toward menopause among married middle-aged adults. Women Health 2002; 36: 55-68.

[7] Mansfield PK, Koch PB, Gierach G. Husbands' support of their perimenopausal wives. Women Health 2003; 38: 97-112.

[8] World Health Organization (WHO). Research on the menopause in the 1990s: WHO Technical Report Series. Genf: World Health Organization; 1996.

[9] Morris E, Rymer J. Menopausal symptoms. Clin Evid 2003; : 2138-2150.

[10] Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571-580.

[11] Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, et al.. Management of menopause-related symptoms. Evidence Report / Technology Assessment No. 120. Rockville: Agency of Healthcare Research and Quality (AHRQ). 2005.

[12] Melby MK, Lock M, Kaufert P. Culture and symptom reporting at menopause. Hum Reprod Update 2005; 11: 495-512.

[13] Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. 2003. ( [www.mrw.interscience.wiley.com])

[14] Frackiewicz EJ, Cutler NR. Women's health care during the perimenopause. J Am Pharm Assoc 2000; 40: 800-811.

[15] Soares CN, Cohen LS. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J 2001; 119: 78-83.

[16] Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998; 351: 1425-1427.

[17] Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997; 95: 252-264. ( [circ.ahajournals.org])

[18] Lawlor DA, Ebrahim S, Davey Smith G. Role of endogenous oestrogen in aetiology of coronary heart disease: analysis of age related trends in coronary heart disease and breast cancer in England and Wales and Japan. BMJ 2002; 325: 311-312.

[19] McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14: 103-115.

[20] Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now?. Lancet 2005; 366: 409-421.

[21] Bertero C. What do women think about menopause? A qualitative study of women's expectations, apprehensions and knowledge about the climacteric period. Int Nurs Rev 2003; 50: 109-118.

[22] Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning?. Menopause 2000; 7: 297-309.

[23] Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004; 104: 824-836.

[24] Asikainen TM, Kukkonen-Harjula K, Miilunpalo S. Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials. Sports Med 2004; 34: 753-778.

[25] Kessel B, Kroneneberg F. The role of complementary and alternative medicine in management of menopausal symptoms. Endocrinol Metab Clin N Am 2004; 33: 717-739.

[26] Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002; 100: 18-25.

[27] Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004; 65: 995-1016.

[28] Keller C, Fullerton J, Mobley C. Supplemental and complementary alternatives to hormone replacement therapy. J Am Acad Nurse Pract 1999; 11: 187-198.

[29] Murkies AL, Wilcox G, Davis SR. Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 1998; 83: 297-303.

[30] Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms - a systematic review. Maturitas 2004; 47: 1-9.

[31] Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003; 10: 465-476.

[32] Dog LT, Powell KL, Weisman SM. Critical evaluation of the safety of Climicifuga racemosa in menopause symptom relief. Menopause 2003; 10: 299-313.

[33] EMEA Committee on Herbal Medicinal Products. Annex 1: Assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, root). London: EMEA. 8 May 2007. [www.emea.europa.eu]Accessed 2007- 5- 8

[34] Somboonporn W, Davis S, Bell R, Seif MW. Testosterone for peri- and postmenopausal women. 2005. ( [www.mrw.interscience.wiley.com])

[35] Farquhar CM, Marjoribanks J, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. 2005. ( [www.mrw.interscience.wiley.com])

[36] Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Änderung der Zulassung für die Arzneimittel: Estrogen- und Estrogen- Gestagen-haltige Arzneimittel zur Hormonsubstitution. 0. ( [www.bfarm.de])

[37] Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). BfArM informiert über neue Ergebnisse zur Hormontherapie mit Tibolon nach den Wechseljahren. 0. ( [www.bfarm.de])

[38] Medicines and Healthcare products Regulatory Agency (MHRA). Latest data on HRT from the UK Million Women Study. 2005. ( [www.mhra.gov.uk])

[39] Medicines and Healthcare products Regulatory Agency (MHRA). Questions and answers related to hormone replacement therapy and endometrial cancer. 0. ( [www.mhra.gov.uk])

[40] Medicines and Healthcare products Regulatory Agency (MHRA). Safety of HRT. 0. ( [www.mhra.gov.uk])

[41] Bundesverband der Pharmazeutischen Industrie (BPI), Verband Forschender Arzneimittelhersteller (VFA), Bundesfachverband der Arzneimittel-Hersteller (BAH), Deutscher Generikaverband. Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Frankfurt/ Main: Rote Liste Service. 2004.

[42] Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. 2004. ( [www.mrw.interscience.wiley.com])

[43] Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610-1620.

[44] Gabriel-Sanchez R, Carmona L, Roque M, Sanchez-Gomez LM, Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. 2005. ( [www.mrw.interscience.wiley.com])

[45] Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. 2003. ( [www.mrw.interscience.wiley.com])

[46] Norman RJ, Flight IHK, Rees MCP. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. 1999. ( [www.mrw.interscience.wiley.com])

[47] Food and Drug Administration (FDA). Estrogen and estrogen with progestin therapies for postmenopausal women. 0. ( [www.fda.gov])

[48] Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006; 113: 5-14.

[49] Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005; 92: 2049-2058.

[50] Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M et al.. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294: 183-193.

• Created (German version): February 14th 2006 10:00
• Last update: September 17th 2007 14:51
• History: Show list